RU2017103675A - Способ размещения в цитоплазме антител в виде полного иммуноглобулина путем проникновения антител через клеточную мембрану и его применение - Google Patents
Способ размещения в цитоплазме антител в виде полного иммуноглобулина путем проникновения антител через клеточную мембрану и его применение Download PDFInfo
- Publication number
- RU2017103675A RU2017103675A RU2017103675A RU2017103675A RU2017103675A RU 2017103675 A RU2017103675 A RU 2017103675A RU 2017103675 A RU2017103675 A RU 2017103675A RU 2017103675 A RU2017103675 A RU 2017103675A RU 2017103675 A RU2017103675 A RU 2017103675A
- Authority
- RU
- Russia
- Prior art keywords
- antibody
- variable region
- amino acid
- acid sequence
- light chain
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 20
- 108060003951 Immunoglobulin Proteins 0.000 title claims 3
- 102000018358 immunoglobulin Human genes 0.000 title claims 3
- 230000001413 cellular effect Effects 0.000 title 1
- 239000012528 membrane Substances 0.000 title 1
- 150000001413 amino acids Chemical group 0.000 claims 36
- 210000000172 cytosol Anatomy 0.000 claims 16
- 235000001014 amino acid Nutrition 0.000 claims 12
- 229940024606 amino acid Drugs 0.000 claims 9
- 235000018102 proteins Nutrition 0.000 claims 9
- 102000004169 proteins and genes Human genes 0.000 claims 9
- 108090000623 proteins and genes Proteins 0.000 claims 9
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 6
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 6
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 6
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 6
- 230000035515 penetration Effects 0.000 claims 6
- 239000004474 valine Substances 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 4
- 239000004472 Lysine Substances 0.000 claims 4
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 4
- 239000004473 Threonine Substances 0.000 claims 4
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 4
- 150000002632 lipids Chemical class 0.000 claims 4
- 229920002521 macromolecule Polymers 0.000 claims 4
- 210000003463 organelle Anatomy 0.000 claims 4
- 210000000170 cell membrane Anatomy 0.000 claims 3
- 239000002502 liposome Substances 0.000 claims 3
- 230000004807 localization Effects 0.000 claims 3
- 239000002105 nanoparticle Substances 0.000 claims 3
- 238000002360 preparation method Methods 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 230000033616 DNA repair Effects 0.000 claims 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 235000004279 alanine Nutrition 0.000 claims 2
- 125000003368 amide group Chemical group 0.000 claims 2
- 235000003704 aspartic acid Nutrition 0.000 claims 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 230000022131 cell cycle Effects 0.000 claims 2
- 230000010261 cell growth Effects 0.000 claims 2
- 230000004663 cell proliferation Effects 0.000 claims 2
- 230000012202 endocytosis Effects 0.000 claims 2
- 210000002472 endoplasmic reticulum Anatomy 0.000 claims 2
- 210000001163 endosome Anatomy 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 230000010189 intracellular transport Effects 0.000 claims 2
- 229960000310 isoleucine Drugs 0.000 claims 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 2
- 229930182817 methionine Natural products 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 210000003470 mitochondria Anatomy 0.000 claims 2
- 210000004940 nucleus Anatomy 0.000 claims 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims 2
- 230000010076 replication Effects 0.000 claims 2
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 2
- 230000035897 transcription Effects 0.000 claims 2
- 238000013518 transcription Methods 0.000 claims 2
- 230000014616 translation Effects 0.000 claims 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/80—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
- C07K2317/82—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies functional in the cytoplasm, the inner aspect of the cell membrane, the nucleus or the mitochondria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20140092673 | 2014-07-22 | ||
| KR10-2014-0092673 | 2014-07-22 | ||
| KR1020150103163A KR101602870B1 (ko) | 2014-07-22 | 2015-07-21 | 완전한 이뮤노글로불린 형태의 항체를 세포막을 투과하여 세포질에 위치시키는 방법 및 그의 이용 |
| KR10-2015-0103163 | 2015-07-21 | ||
| PCT/KR2015/007626 WO2016013870A1 (ko) | 2014-07-22 | 2015-07-22 | 완전한 이뮤노글로불린 형태의 항체를 세포막을 투과하여 세포질에 위치시키는 방법 및 그의 이용 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2017103675A true RU2017103675A (ru) | 2018-08-06 |
Family
ID=55354088
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017103675A RU2017103675A (ru) | 2014-07-22 | 2015-07-22 | Способ размещения в цитоплазме антител в виде полного иммуноглобулина путем проникновения антител через клеточную мембрану и его применение |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10844136B2 (enExample) |
| EP (1) | EP3173428B1 (enExample) |
| JP (1) | JP6595592B2 (enExample) |
| KR (1) | KR101602870B1 (enExample) |
| CN (1) | CN107001481A (enExample) |
| AU (1) | AU2015292955B2 (enExample) |
| BR (1) | BR112017001304A2 (enExample) |
| CA (1) | CA2955272A1 (enExample) |
| IL (1) | IL250203B (enExample) |
| RU (1) | RU2017103675A (enExample) |
| ZA (1) | ZA201700488B (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3597665A1 (en) | 2011-04-01 | 2020-01-22 | Yale University, Inc. | Cell-penetrating anti-dna antibodies and uses thereof to inhibit dna repair |
| KR101602876B1 (ko) | 2014-07-22 | 2016-03-11 | 아주대학교산학협력단 | 완전한 이뮤노글로불린 형태의 세포질 침투능을 갖는 항체를 이용하여 세포내 활성화된 ras를 억제하는 방법 및 그의 이용 |
| KR101602870B1 (ko) | 2014-07-22 | 2016-03-21 | 아주대학교산학협력단 | 완전한 이뮤노글로불린 형태의 항체를 세포막을 투과하여 세포질에 위치시키는 방법 및 그의 이용 |
| KR102000000B1 (ko) * | 2016-05-27 | 2019-07-12 | 오름테라퓨틱 주식회사 | 항체에 엔도좀 탈출능을 부여하는 엔도좀 탈출 구조 모티프 및 이의 활용 |
| WO2017204606A1 (ko) | 2016-05-27 | 2017-11-30 | 오름테라퓨틱 주식회사 | 세포질 침투 항체 및 이의 용도 |
| WO2017218824A1 (en) | 2016-06-15 | 2017-12-21 | Yale University | Anti-guanosine antibody as a molecular delivery vehicle |
| EP3471777A1 (en) | 2016-06-15 | 2019-04-24 | Yale University | Antibody-mediated autocatalytic, targeted delivery of nanocarriers to tumors |
| CN111936521A (zh) | 2017-11-16 | 2020-11-13 | 奥隆制药 | 通过内化到细胞胞浆中抑制细胞中活化的Ras的抗体及其用途 |
| WO2019152806A1 (en) * | 2018-02-01 | 2019-08-08 | Yale University | Compositions and methods for enhancing nuclear translocation |
| CN112218621A (zh) * | 2018-04-10 | 2021-01-12 | 西北大学 | 包含基于靶向亲和域的膜蛋白的胞外囊泡 |
| US10787487B2 (en) | 2018-06-21 | 2020-09-29 | Orum Therapeutics Inc. | Cell/tissue-specific cell-penetrating antibodies |
| JP2021532135A (ja) * | 2018-07-23 | 2021-11-25 | 中外製薬株式会社 | 標的細胞特異的な細胞質侵入抗原結合分子 |
| CN110759996B (zh) * | 2018-07-27 | 2022-09-06 | 深圳康体生命科技有限公司 | 一种gfp抗体 |
| CN108949565B (zh) * | 2018-09-26 | 2024-09-06 | 中国科学技术大学 | 用于红细胞负载冻干保护剂的装置及方法 |
| WO2020221849A1 (en) * | 2019-05-01 | 2020-11-05 | Universidade De Santiago De Compostela | Intracellular delivery of anti-kras antibodies formulated into nanocapsules |
| EP4101866A4 (en) | 2020-02-06 | 2024-04-24 | Ajou University Industry-Academic Cooperation Foundation | Fusion antibody for presenting antigen-derived t cell antigen epitope or peptide containing same on cell surface, and composition comprising same |
| IL295788A (en) * | 2020-02-24 | 2022-10-01 | Oblique Therapeutics Ab | epitopes and kras antibodies |
| CN115397868A (zh) * | 2020-03-30 | 2022-11-25 | 埃博灵克斯股份有限公司 | 用于产生和纯化多价免疫球蛋白单可变域的方法 |
| CR20220598A (es) * | 2020-04-30 | 2023-01-17 | Genentech Inc | Anticuerpos específicos para kras y sus usos |
| EP4375294A1 (en) | 2021-07-20 | 2024-05-29 | Ajou University Industry-Academic Cooperation Foundation | Cell-penetrating degrading antibody that penetrates into cells to degrade and remove target protein and use thereof |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2706486B1 (fr) | 1993-06-16 | 1995-09-01 | Rhone Poulenc Rorer Sa | Séquences nucléiques, vecteurs les contenant, compositions pharmaceutiques et utilisations thérapeutiques. |
| CN1241574A (zh) * | 1998-07-02 | 2000-01-19 | 中国人民解放军第四军医大学 | 抗肝癌单克隆抗体HAb25及其单链抗体和双功能抗体 |
| WO2003077945A1 (en) | 2002-03-14 | 2003-09-25 | Medical Research Council | Intracellular antibodies |
| GB0226727D0 (en) | 2002-11-15 | 2002-12-24 | Medical Res Council | Intrabodies |
| WO2004046188A2 (en) | 2002-11-15 | 2004-06-03 | Medical Research Council | Anti-activated ras antibodies |
| CA2647102A1 (en) | 2006-03-27 | 2007-11-22 | Globeimmune, Inc. | Ras mutation and compositions and methods related thereto |
| EA201500156A3 (ru) | 2008-01-03 | 2017-09-29 | Дзе Скриппс Рисерч Инститьют | Доставка антител посредством модульного домена распознавания |
| KR100849941B1 (ko) * | 2008-04-29 | 2008-08-01 | 원우이에프엔지니어링주식회사 | 열 및 연기 화재감지장치 복합시험기 |
| JP2011519370A (ja) * | 2008-04-30 | 2011-07-07 | アジョウ・ユニヴァーシティ・インダストリー−アカデミック・コーオペレーション・ファンデーション | 癌細胞の細胞死を誘導する抗核酸抗体及びこれを用いた癌予防または治療用組成物 |
| KR101075123B1 (ko) | 2008-10-24 | 2011-10-19 | 아주대학교산학협력단 | 핵산가수분해 능 및 암세포내 침투능력을 갖는 인간화된 항체 및 그 용도 |
| WO2010056043A2 (en) * | 2008-11-11 | 2010-05-20 | Ajou University Industry-Academic Cooperation Foundation | Cell-penetrating, sequence-specific and nucleic acid-hydrolyzing antibody, method for preparing the same and pharmaceutical composition comprising the same |
| CN101402675B (zh) | 2008-11-28 | 2012-05-30 | 中国人民解放军第三军医大学第三附属医院 | 一种靶向抑制ανβ3阳性细胞增殖的环肽 |
| US20110053829A1 (en) | 2009-09-03 | 2011-03-03 | Curevac Gmbh | Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids |
| WO2011140151A1 (en) | 2010-05-04 | 2011-11-10 | Dyax Corp. | Antibodies against epidermal growth factor receptor (egfr) |
| GB201103631D0 (en) | 2011-03-03 | 2011-04-13 | Univ Leeds | Identification of candidate therapeutics |
| EP3597665A1 (en) | 2011-04-01 | 2020-01-22 | Yale University, Inc. | Cell-penetrating anti-dna antibodies and uses thereof to inhibit dna repair |
| US9283272B2 (en) | 2012-03-30 | 2016-03-15 | The United States Of America As Represented By The Department Of Veterans Affairs | Targeting intracellular target-binding determinants with intracellular antibodies |
| US9815866B2 (en) | 2012-09-14 | 2017-11-14 | Japanese Foundation For Cancer Research | Peptides that bind to epithelial cell adhesion molecule |
| US10011635B2 (en) | 2013-09-27 | 2018-07-03 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Cyclic peptide conjugates and methods of use |
| KR101602876B1 (ko) | 2014-07-22 | 2016-03-11 | 아주대학교산학협력단 | 완전한 이뮤노글로불린 형태의 세포질 침투능을 갖는 항체를 이용하여 세포내 활성화된 ras를 억제하는 방법 및 그의 이용 |
| KR101602870B1 (ko) | 2014-07-22 | 2016-03-21 | 아주대학교산학협력단 | 완전한 이뮤노글로불린 형태의 항체를 세포막을 투과하여 세포질에 위치시키는 방법 및 그의 이용 |
| WO2016013871A1 (ko) | 2014-07-22 | 2016-01-28 | 아주대학교산학협력단 | 완전한 이뮤노글로불린 형태의 세포질 침투능을 갖는 항체를 이용하여 세포내 활성화된 ras를 억제하는 방법 및 그의 이용 |
| CN114456272A (zh) | 2015-04-03 | 2022-05-10 | 优瑞科生物技术公司 | 靶向afp肽/mhc复合体的构建体及其用途 |
| KR101790669B1 (ko) | 2015-10-14 | 2017-10-26 | 아주대학교산학협력단 | 개선된 분할 녹색 형광 단백질 상보 시스템 및 이의 용도 |
| WO2017204606A1 (ko) | 2016-05-27 | 2017-11-30 | 오름테라퓨틱 주식회사 | 세포질 침투 항체 및 이의 용도 |
| KR101836392B1 (ko) | 2016-08-17 | 2018-03-08 | 한림대학교 산학협력단 | 사이클릭 펩타이드를 포함하는 백신 조성물, 사이클릭 펩타이드에 대한 항체 또는 이를 포함하는 항암 조성물 |
| CN111936521A (zh) | 2017-11-16 | 2020-11-13 | 奥隆制药 | 通过内化到细胞胞浆中抑制细胞中活化的Ras的抗体及其用途 |
| US10787487B2 (en) | 2018-06-21 | 2020-09-29 | Orum Therapeutics Inc. | Cell/tissue-specific cell-penetrating antibodies |
-
2015
- 2015-07-21 KR KR1020150103163A patent/KR101602870B1/ko not_active Expired - Fee Related
- 2015-07-22 RU RU2017103675A patent/RU2017103675A/ru not_active Application Discontinuation
- 2015-07-22 AU AU2015292955A patent/AU2015292955B2/en not_active Ceased
- 2015-07-22 JP JP2017525495A patent/JP6595592B2/ja not_active Expired - Fee Related
- 2015-07-22 EP EP15825418.5A patent/EP3173428B1/en active Active
- 2015-07-22 CN CN201580045139.0A patent/CN107001481A/zh active Pending
- 2015-07-22 BR BR112017001304-5A patent/BR112017001304A2/pt not_active Application Discontinuation
- 2015-07-22 CA CA2955272A patent/CA2955272A1/en not_active Abandoned
- 2015-07-22 US US15/327,369 patent/US10844136B2/en not_active Expired - Fee Related
-
2017
- 2017-01-19 IL IL250203A patent/IL250203B/en not_active IP Right Cessation
- 2017-01-20 ZA ZA2017/00488A patent/ZA201700488B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3173428B1 (en) | 2020-02-19 |
| JP6595592B2 (ja) | 2019-10-23 |
| ZA201700488B (en) | 2018-12-19 |
| EP3173428A1 (en) | 2017-05-31 |
| CN107001481A (zh) | 2017-08-01 |
| AU2015292955B2 (en) | 2020-08-13 |
| JP2017529097A (ja) | 2017-10-05 |
| EP3173428A4 (en) | 2018-01-24 |
| US10844136B2 (en) | 2020-11-24 |
| US20170218084A1 (en) | 2017-08-03 |
| CA2955272A1 (en) | 2016-01-28 |
| IL250203A0 (en) | 2017-03-30 |
| KR20160011598A (ko) | 2016-02-01 |
| AU2015292955A1 (en) | 2017-02-09 |
| BR112017001304A2 (pt) | 2018-01-30 |
| IL250203B (en) | 2020-09-30 |
| KR101602870B1 (ko) | 2016-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2017103675A (ru) | Способ размещения в цитоплазме антител в виде полного иммуноглобулина путем проникновения антител через клеточную мембрану и его применение | |
| RU2017103679A (ru) | Способ ингибирования внутриклеточного активированного ras с помощью интакного антитела иммуноглобулинового типа, обладающего способностью к проникновению в цитозоль, и его применение | |
| JP2017529097A5 (enExample) | ||
| AU2015295936B2 (en) | Anti-CTLA4 monoclonal antibody or antigen binding fragment thereof, medicinal composition and use | |
| HRP20220918T1 (hr) | Anti-transtiretinska antitijela | |
| HRP20200036T1 (hr) | Postupci liječenja tauopatije | |
| JP2017529870A5 (enExample) | ||
| IL278014B2 (en) | Anti-myostatin antibodies, polypeptides containing variable FC regions and methods of use | |
| HRP20240997T1 (hr) | Varijabilni fragmenti antitijela koji se mogu umetnuti i modificirane α1-α2 domene nkg2d liganada, kao i neprirodni nkg2d ligandi koji se vežu za neprirodne nkg2d receptore | |
| HRP20190799T1 (hr) | Imunocitokini na bazi il-15 i sushi domene il-15r alfa | |
| RU2018113505A (ru) | Il-8-связывающие антитела и их применения | |
| EA202190669A1 (ru) | Процесс получения вакцинной композиции | |
| HRP20231578T1 (hr) | Molekule protutijela na april i njihove uporabe | |
| EA201391761A1 (ru) | Анти-альфа-синуклеинсвязывающие молекулы | |
| HRP20221538T1 (hr) | Anti-transtiretinska antitijela | |
| IL275497B (en) | Serum proteins with type iii fibronectin binding domains | |
| RU2015144105A (ru) | Антитела к гепсидину и их применения | |
| EP3539982A3 (en) | Engineered antibody constant regions for site-specific conjugation and methods and uses therefor | |
| RU2018141360A (ru) | Contorsbody - одноцепочечный связывающий мишень агент | |
| BR112015022872A2 (pt) | polipeptídeos grampeados e costurados, seu uso, seu método de preparação, composição que os compreende e aminoácido | |
| HRP20190752T1 (hr) | Novo protutijelo protiv ljudskog receptora tslp | |
| HRP20240996T1 (hr) | Prefuzija rsv f proteina i njihova uporaba | |
| HRP20191704T1 (hr) | Multispecifična protutijela | |
| RU2012111708A (ru) | Гуманизированные антитела к cdcp1 | |
| BR112014030797A2 (pt) | epítopo de peptídeo isolado, proteína recombinante, molécula de ácido nucléico isolada, vetor, célula hospedeira, método para preparar o epítopo de peptídeo ou mutante do mesmo, vacina de proteína, uso do epítopo de peptídeo ou mutante do mesmo, vacina de gene, uso da molécula de ácido nucléico, composição farmacêutica, anticorpo monoclonal e um fragmento de ligação ao antígeno do mesmo, linha de célula de hibridoma, kit, método para detecção da presença ou nível da proteína hbsag em uma amostra e uso do anticorpo monoclonal ou fragmento de ligação ao antígeno do mesmo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20200204 |